{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:21:42Z","timestamp":1792156902874,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["ZIA AI001175"],"award-info":[{"award-number":["ZIA AI001175"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED\/APS-1) is a monogenic disorder of failed central tolerance. Interferon-\u03b3-driven inflammation in APECED underlies multiorgan autoimmunity and chronic mucocutaneous candidiasis and is targetable with JAK1\/2 inhibition. Whether early cytokine blockade can avert irreversible endocrine failure is currently unknown. Here, we describe two individuals with APECED who developed evolving autoimmune hypoparathyroidism and hypergonadotropic hypogonadism. Treatment with the JAK1\/2 inhibitor ruxolitinib halted progression and reversed biochemical and clinical abnormalities, preserving parathyroid and gonadal function. These findings provide clinical evidence that timely JAK-STAT pathway inhibition can intercept evolving endocrine autoimmunity in APECED. More broadly, they advance a disease-interception paradigm in which early, pathway-directed cytokine blockade may alter the natural history of autoimmune endocrinopathies.<\/jats:p>","DOI":"10.1038\/s41467-026-76285-x","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:43:06Z","timestamp":1785566586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ruxolitinib prevents irreversible autoimmune endocrinopathies in APECED"],"prefix":"10.1038","volume":"17","author":[{"given":"Joseph","family":"Pechacek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taura","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"dos Santos Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princess","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey B.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-048X","authenticated-orcid":false,"given":"Peter D.","family":"Burbelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Colton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5474-3446","authenticated-orcid":false,"given":"Herodes","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sacta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana E.","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Loomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-5318","authenticated-orcid":false,"given":"Neil","family":"Romberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-5464","authenticated-orcid":false,"given":"Steven M.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-6289","authenticated-orcid":false,"given":"Theo","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-5188","authenticated-orcid":false,"given":"Karen K.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1439","authenticated-orcid":false,"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4994-9500","authenticated-orcid":false,"given":"Michail S.","family":"Lionakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"76285_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/imr.12714","volume":"287","author":"GM Constantine","year":"2019","unstructured":"Constantine, G. M. & Lionakis, M. S. Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Immunol. Rev. 287, 103\u2013120 (2019).","journal-title":"Immunol. Rev."},{"key":"76285_CR2","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1126\/science.1075958","volume":"298","author":"MS Anderson","year":"2002","unstructured":"Anderson, M. S. et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 298, 1395\u20131401 (2002).","journal-title":"Science"},{"key":"76285_CR3","doi-asserted-by":"publisher","unstructured":"Ferre, E. M. et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 1, https:\/\/doi.org\/10.1172\/jci.insight.88782 (2016).","DOI":"10.1172\/jci.insight.88782"},{"key":"76285_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hep.31421","volume":"73","author":"DM Chascsa","year":"2021","unstructured":"Chascsa, D. M. et al. APECED-Associated hepatitis: clinical, biochemical, histological and treatment data from a large, predominantly American cohort. Hepatology 73, 1088\u20131104 (2021).","journal-title":"Hepatology"},{"key":"76285_CR5","doi-asserted-by":"publisher","unstructured":"Ferre, E. M. N. et al. Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Sci. Transl. Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aav5597 (2019).","DOI":"10.1126\/scitranslmed.aav5597"},{"key":"76285_CR6","doi-asserted-by":"publisher","unstructured":"Ferre EMN, P. J. et al. Performance of expanded diagnostic criteria for APECED in independent cohorts and implications for earlier diagnosis. JCI Insight 11, https:\/\/doi.org\/10.1172\/jci.insight.203021 (2026).","DOI":"10.1172\/jci.insight.203021"},{"key":"76285_CR7","doi-asserted-by":"publisher","unstructured":"Break, T. J.et al. Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. Science 371, https:\/\/doi.org\/10.1126\/science.aay5731 (2021).","DOI":"10.1126\/science.aay5731"},{"key":"76285_CR8","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1056\/NEJMoa2312665","volume":"390","author":"V Oikonomou","year":"2024","unstructured":"Oikonomou, V. et al. The role of interferon-gamma in autoimmune polyendocrine syndrome type 1. N. Engl. J. Med. 390, 1873\u20131884 (2024).","journal-title":"N. Engl. J. Med."},{"key":"76285_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10875-023-01629-x","volume":"44","author":"R Levy","year":"2023","unstructured":"Levy, R. et al. Ruxolitinib rescues multiorgan clinical autoimmunity in patients with APS-1. J. Clin. Immunol. 44, 5 (2023).","journal-title":"J. Clin. Immunol."},{"key":"76285_CR10","doi-asserted-by":"publisher","first-page":"106362","DOI":"10.1016\/j.phrs.2022.106362","volume":"183","author":"R Roskoski Jr.","year":"2022","unstructured":"Roskoski, R. Jr. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharm. Res. 183, 106362 (2022).","journal-title":"Pharm. Res."},{"key":"76285_CR11","doi-asserted-by":"crossref","unstructured":"Hadjiyannis, Y. et al. Selective JAK1 inhibition remits multiorgan autoimmunity in a patient with refractory autoimmune polyendocrine syndrome type 1. J. Allergy Clin. Immunol. 155, 2080\u20132083 (2025).","DOI":"10.1016\/j.jaci.2025.03.026"},{"key":"76285_CR12","doi-asserted-by":"publisher","unstructured":"Heller, E., Dos Santos Dias, L. & Lionakis, M. S. Selective JAK inhibition reveals paradoxical and hierarchical control of interferon-gamma-driven autoimmunity in AIRE deficiency. Preprint at https:\/\/doi.org\/10.64898\/2026.03.05.709894 (2026).","DOI":"10.64898\/2026.03.05.709894"},{"key":"76285_CR13","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Ramos","year":"2023","unstructured":"Ramos, E. L. et al. Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes. N. Engl. J. Med. 389, 2151\u20132161 (2023).","journal-title":"N. Engl. J. Med."},{"key":"76285_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2337\/dc25-1444","volume":"49","author":"CS Wilson","year":"2026","unstructured":"Wilson, C. S. et al. Use of teplizumab to modulate stage 2 type 1 diabetes in two individuals with autoimmune polyendocrine syndrome 1. Diab. Care 49, 111\u2013117 (2026).","journal-title":"Diab. Care"},{"key":"76285_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-019-0309-6","volume":"17","author":"O Halyabar","year":"2019","unstructured":"Halyabar, O. et al. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr. Rheumatol. Online J. 17, 7 (2019).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"76285_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1210\/jc.2003-030279","volume":"89","author":"A Soderbergh","year":"2004","unstructured":"Soderbergh, A. et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J. Clin. Endocrinol. Metab. 89, 557\u2013562 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"76285_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1210\/jc.2005-1538","volume":"91","author":"T Ulinski","year":"2006","unstructured":"Ulinski, T. et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome with renal failure: impact of posttransplant immunosuppression on disease activity. J. Clin. Endocrinol. Metab. 91, 192\u2013195 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"76285_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/dc08-2339","volume":"32","author":"P Gillard","year":"2009","unstructured":"Gillard, P. et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies. Diab. Care 32, 1817\u20131819 (2009).","journal-title":"Diab. Care"},{"key":"76285_CR19","first-page":"1062","volume":"135","author":"N Molle","year":"2020","unstructured":"Molle, N. et al. Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2\/STAT3. Blood 135, 1062\u20131066 (2020).","journal-title":"Blood"},{"key":"76285_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12986-021-00569-w","volume":"18","author":"H Liu","year":"2021","unstructured":"Liu, H., Du, T., Li, C. & Yang, G. STAT3 phosphorylation in central leptin resistance. Nutr. Metab. 18, 39 (2021).","journal-title":"Nutr. Metab."},{"key":"76285_CR21","doi-asserted-by":"publisher","first-page":"108851","DOI":"10.1016\/j.clim.2021.108851","volume":"231","author":"I Hetemaki","year":"2021","unstructured":"Hetemaki, I. et al. Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections. Clin. Immunol. 231, 108851 (2021).","journal-title":"Clin. Immunol."},{"key":"76285_CR22","doi-asserted-by":"publisher","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","volume":"14","author":"Q Xu","year":"2023","unstructured":"Xu, Q., He, L. & Yin, Y. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. Front. Pharm. 14, 1241954 (2023).","journal-title":"Front. Pharm."},{"key":"76285_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1182\/blood.2025030976","volume":"147","author":"JM Rocco","year":"2026","unstructured":"Rocco, J. M. et al. CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis. Blood 147, 960\u2013972 (2026).","journal-title":"Blood"},{"key":"76285_CR24","doi-asserted-by":"publisher","first-page":"152812","DOI":"10.1016\/j.semarthrit.2025.152812","volume":"74","author":"A De Matteis","year":"2025","unstructured":"De Matteis, A. et al. Traditional laboratory parameters and IFNgamma-related biomarkers in the diagnosis and management of MAS. Semin. Arthritis Rheum. 74, 152812 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"76285_CR25","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.4049\/jimmunol.1400223","volume":"193","author":"M Gimenez-Barcons","year":"2014","unstructured":"Gimenez-Barcons, M. et al. Autoimmune predisposition in Down syndrome may result from a partial central tolerance failure due to insufficient intrathymic expression of AIRE and peripheral antigens. J. Immunol. 193, 3872\u20133879 (2014).","journal-title":"J. Immunol."},{"key":"76285_CR26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMra1713301","volume":"378","author":"ES Husebye","year":"2018","unstructured":"Husebye, E. S., Anderson, M. S. & Kampe, O. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 378, 1132\u20131141 (2018).","journal-title":"N. Engl. J. Med."},{"key":"76285_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41574-024-01075-8","volume":"21","author":"S Khan","year":"2025","unstructured":"Khan, S. & Khan, A. A. Hypoparathyroidism: diagnosis, management and emerging therapies. Nat. Rev. Endocrinol. 21, 360\u2013374 (2025).","journal-title":"Nat. Rev. Endocrinol."},{"key":"76285_CR28","doi-asserted-by":"publisher","first-page":"e6288","DOI":"10.1002\/ccr3.6288","volume":"10","author":"L Gadakchi","year":"2022","unstructured":"Gadakchi, L., Ebrahimi, A. A., Sadra, V., Moslemi, M. & Khabbazi, A. Hypoparathyroidism as one of the initial presentations of systemic lupus erythematosus. Clin. Case Rep. 10, e6288 (2022).","journal-title":"Clin. Case Rep."},{"key":"76285_CR29","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.4049\/jimmunol.181.3.2211","volume":"181","author":"M Harigai","year":"2008","unstructured":"Harigai, M. et al. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator\/B cell-activating factor\/TNF ligand superfamily-13B. J. Immunol. 181, 2211\u20132219 (2008).","journal-title":"J. Immunol."},{"key":"76285_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.autrev.2014.01.003","volume":"13","author":"CA Silva","year":"2014","unstructured":"Silva, C. A. et al. Autoimmune primary ovarian insufficiency. Autoimmun. Rev. 13, 427\u2013430 (2014).","journal-title":"Autoimmun. Rev."},{"key":"76285_CR31","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1073\/pnas.020522597","volume":"97","author":"P Caturegli","year":"2000","unstructured":"Caturegli, P. et al. Hypothyroidism in transgenic mice expressing IFN-gamma in the thyroid. Proc. Natl. Acad. Sci. USA 97, 1719\u20131724 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76285_CR32","doi-asserted-by":"publisher","first-page":"1020709","DOI":"10.3389\/fpubh.2022.1020709","volume":"10","author":"X Hu","year":"2022","unstructured":"Hu, X. et al. Global prevalence and epidemiological trends of Hashimoto\u2019s thyroiditis in adults: A systematic review and meta-analysis. Front. Public Health 10, 1020709 (2022).","journal-title":"Front. Public Health"},{"key":"76285_CR33","doi-asserted-by":"crossref","unstructured":"Burbelo, P. D., Ching, K. H., Klimavicz, C. M. & Iadarola, M. J. Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS). J. Vis. Exp. 32, 1549 (2009).","DOI":"10.3791\/1549-v"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76285-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:04:33Z","timestamp":1788134673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76285-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76285"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76285-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9295"}}